Development of chronic renal disease (chronic kidney disease; CKD) is a common consequence of many medical conditions, and its prevalence is rising. Predominant causes of CKD are hypertension and diabetes mellitus. Determination of Glomerular Filtration Rate (GFR) is one of the most common tests employed and a part of all standard blood panels. GFR is used to assess kidney health and kidney function. GFR is consequently the most important marker for impaired renal function.
Currently, GFR determination is based on an estimation using clinical data and blood based biomarkers such as creatinine. GFR can either be measured (mGFR) by tracer based methods or estimated (eGFR) using clinical data and blood based biomarkers such as creatinine or cystatin C. However, mGFR methods are highly elaborate and time-consuming and eGFR lacks accuracy in a variety of common clinical situations. As a consequence clinical decision making is difficult especially early when intervention may retard progression to end-stage renal disease.
1. 2011–2014 National Health and Nutrition Examination Survey and the CKD Epidemiology Collaboration (CKD-EPI) equation.
numares developed a novel multi-parametric serum test called AXINON®Clearance Check to assess kidney function and significantly improve on the current standard of serum creatinine-based estimated Glomerular Filtration Rate (eGFR). Our NMR (nuclear magnetic resonance)-based early GFR data determination is more accurate than creatinine based, conventional eGFR and comparable to tracer based mGFR methods.
Using the metabolomics approach and numares’ Magnetic Group Signaling (MGS®) technology, NMR-based GFR-correlating biomarkers are evaluated to develop defined metabolite constellations displaying impaired glomerular filtration rate.
AXINON® Clearance Check will improve the care of patients by offering an accurate and easy way in kidney disease diagnostics to assess renal function, monitoring kidney disease progression and monitoring of therapies with nephrotoxic drugs.
More information on the AXINON®Clearance Check test system
Go to FAQs
The novel AXINON® Clearance Check test to assess kidney function will be available on the AXINON® IVD System, which produces high-quality, standardized NMR spectra based on numares’ Magnetic Group Signaling (MGS®) technology, which enables a throughput of more than 200 samples per day.
The combination of MGS® with the AXINON® IVD System allows for test-specific spectral analysis with highly-reproducible results. The system is easy to use with one-step sample preparation with ready-to-use reagents requiring minimal operator interaction. The test system is fast and efficient with automation capabilities allowing short hands-on-time and high walk-away capability.
To date, more than 2 million tests have been performed worldwide, using the numares’ technology.
* For Research Use only in the United States. numares’ products are not yet available for sale within the United States; they have not yet been approved or cleared by the U.S. Food and Drug Administration.